Table 4.
Univariate analysis of clinicopathological characteristics associated with survival.
| Variable | Overall survival | ||
|---|---|---|---|
| HR | 95% CI | P | |
| Sex (M/F) | 0.250 | 0.061-1.034 | 0.056 |
| Age (≥45) | 1.114 | 0.612-2.027 | 0.724 |
| HBsAg (positive) | 1.226 | 0.439-3.422 | 0.697 |
| Liver cirrhosis (positive) | 2.570 | 0.354-18.660 | 0.351 |
| HBV-DNA (≥5 × 102 IU/mL) | 0.850 | 0.486-1.813 | 0.850 |
| AFP (≥400 ng/mL) | 1.952 | 1.052-3.624 | 0.034 |
| CTC-NLR | 2.696 | 1.765-4.119 | <0.001 |
| CTC ≥ 20 | 4.211 | 2.131-8.321 | <0.001 |
| NLR ≥ 2.15 | 2.632 | 1.451-4.773 | 0.001 |
| ALB (≥35 g/L) | 0.680 | 0.304-1.522 | 0.348 |
| Tumor size (≥5 cm) | 4.457 | 1.595-12.452 | 0.004 |
| Tumor number (>1) | 2.828 | 1.575-5.075 | <0.001 |
| MVI (positive) | 8.362 | 2.984-23.427 | <0.001 |
| BCLC stage (B-C) | 7.912 | 4.015-15.592 | <0.001 |
| PVTT (positive) | 9.005 | 4.456-18.195 | <0.001 |
AFP: alpha-fetoprotein; ALB: albumin; CTC: circulating tumor cell count; NLR: neutrophil-lymphocyte ratio; BCLC stage: Barcelona Clinic Liver Cancer stage; HBsAg: hepatitis B surface antigen; HBV-DNA: hepatitis B virus DNA; HCC: hepatocellular carcinoma; HR: hazard ratio; MVI: microvascular invasion; PVTT: portal vein tumor thrombosis.